Navigation Links
TOPICA Names Mark W. Davis Vice President of Clinical Development

PALO ALTO, Calif., Feb. 18 /PRNewswire/ -- TOPICA Pharmaceuticals, a privately-held biotechnology company, today announced the appointment of Mark W. Davis as Vice President of Clinical Development.  In this position, Mr. Davis will lead TOPICA's clinical development activities for luliconazole, its lead product candidate, for the treatment of onychomycosis (nail and nail bed fungal infections) and tinea pedis (athlete's foot).  The company expects to initiate a Phase 1/2a trial of luliconazole in the U.S. for onychomycosis during the first quarter of 2010 and to advance luliconazole into a Phase 3 clinical development program for tinea pedis this year.  

"Mark Davis is a very experienced clinical development leader with a solid background in dermatology," said Greg Vontz, president and CEO of TOPICA.  "Mark's understanding of the clinical development process, as well as his long-standing relationship with the FDA's Dermatology Division is vital to TOPICA's success and he will play a major role in our preparation for commercialization of luliconazole."

"Based on luliconazole's strong clinical profile, clinical development programs and previous approval in Japan, as well as TOPICA's robust Phase 2 study in tinea pedis, I believe the compound is poised for terrific success," said Mr. Davis.  "I will be working diligently to advance all of the clinical development programs for luliconazole with a specific near-term focus on leading development efforts in onychomycosis where this anti-fungal therapy could become the first truly effective and safe topical therapy for patients."

Mr. Davis has more than 27 years of experience in the biotechnology, pharmaceutical and medical device industry.  Prior to joining TOPICA, he served in project leadership roles and as head of Clinical Operations at Onyx Pharmaceuticals developing oncology products.  Prior to Onyx, he was Senior Director of Clinical Operations at Connetics Corporation, where he successfully led clinical programs for three dermatologic product approvals in the United States.  Mr. Davis also spent more than 12 years in clinical development at Amgen.  Mr. Davis earned his M.S. in biomedical engineering from the University of Utah and his B.S. in biomedical engineering from the University of California, San Diego.

About Luliconazole

Luliconazole is one of the most potent and broad-spectrum topical antifungal agents. TOPICA is developing luliconazole for onychomycosis, which affects approximately 35 million people in the U.S. Currently approved therapies for onychomycosis are either ineffective or are complicated by the potential of liver toxicity and require hepatic monitoring.  In numerous rigorous preclinical models of onychomycosis, luliconazole has demonstrated rapid penetration and therapeutically effectively levels in the nail bed.  This preclinical profile suggests luliconazole has the potential to be the first highly effective and safe topical therapy for onychomycosis.  The potential annual U.S. market for onychomycosis treatment is estimated at approximately $3 billion.

TOPICA is also developing luliconazole for the treatment of tinea pedis, the most common fungal infection of the skin, affecting about one in every 10 people.  In the U.S. more than 22 million prescriptions are written annually for tinea infections.  Currently approved products for the topical treatment of tinea pedis are only modestly effective, have a high reoccurrence rate and require a month of therapy.  In 2009, TOPICA announced positive results from its Phase 2 clinical trial of luliconazole for tinea pedis.  The results of TOPICA's Phase 2 trial demonstrated that luliconazole was substantially more effective than approved therapies and required half the treatment time.  TOPICA expects to begin its pivotal Phase 3 trials in 2010 to support approval.  

TOPICA has an exclusive license from Nihon Nohyaku Co., Ltd. to develop and market luliconazole in the Americas and Europe.

About TOPICA Pharmaceuticals

TOPICA is a privately-held specialty pharmaceutical company focused on licensing, developing and commercializing topical prescription products to treat the needs of patients with serious nail and skin conditions. Taking advantage of its established trans-Pacific network of scientific and industry contacts, TOPICA has in-licensed its lead product candidate, luliconazole, a topical antifungal agent that is already on the market in Japan. TOPICA is developing luliconazole for the treatment of tinea pedis (athlete's foot) and onychomycosis (fungal infections of the nail). For more information, please visit

SOURCE TOPICA Pharmaceuticals



SOURCE TOPICA Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TOPICA Announces Participation in BioPartnering North America
2. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
3. Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
4. TOPICA Announces Positive Phase 2 Clinical Results for Luliconazole, a Potent Topical Antifungal
5. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
6. ProFibrix Initiates Phase II Clinical Trial of its Lead Topical Hemostat Product Fibrocaps(TM)
7. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
8. Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain
9. NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
10. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
11. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
Post Your Comments:
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
(Date:11/25/2015)... 25, 2015  Linden Care, LLC, a retail specialty ... for patients suffering from chronic pain, said today that ... Restraining Order (TRO) enjoining Express Scripts from unilaterally terminating ... --> --> The company ... legal options. --> --> ...
(Date:11/25/2015)... -- On Tuesday, November 24, 2015, the jury ... Medical Technology, Inc. for product liability and misrepresentation ... device, awarded $11 million in favor of Plaintiff ... three days of deliberations, the jury found that ... and unreasonably dangerous, and that Wright Medical made ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, a ... to celebrate their sobriety and show through pictures what a positive difference it ... this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. ...
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon ... programs, launches new Wimbledon Athletics Facebook page to educate the public, ... unsuspected cardiac abnormalities. About 2,000 people under the age of 25 die from ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Smiles by ... TMJ Disorder, Bruxism, and moderate facial wrinkling. While many patients are aware of the ... the great success Botox® delivers to those suffering with discomfort, soreness, and pain as ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... of music, friendships, and learning in its 65th Anniversary Brillianteen Revue, scheduled for ... , For 65 years, Brillianteen has been a treasured tradition for ...
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against ... nation’s roadways has dropped below 10,000 for the first time since 2011. In 2014, ... , According to data released by the National Highway Traffic Safety Administration (NHTSA), 32,675 ...
Breaking Medicine News(10 mins):